Fibrinogen facilitates the anti-tumor effect of nonnative endostatin

Biochemical and Biophysical Research Communications

Volumn 380, Issue 2, 2009, Pages 249-253

  Tang, Huadong ^a,b   Fu, Yan ^a,b   Lei, Qingxin ^a   Han, Qing ^a   Ploplis, Victoria A ^c   Castellino, Francis J ^c   Li, Ling ^a,b   Luo, Yongzhang ^a,b  

^a TSINGHUA UNIVERSITY   (China)

^b Beijing Key Laboratory for Protein Therapeutics   (China)

^c UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Aggregation; Anti tumor; Endostatin; Fibrinogen; Nonnative

Indexed keywords

ENDOSTATIN; FIBRINOGEN; NONNATIVE ENDOSTATIN; RECOMBINANT HUMAN ENDOSTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BLOOD; CANCER INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG ISOLATION; DRUG PROTEIN BINDING; FIBRINOGEN DEFECT; FRACTIONATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; ENDOSTATINS; FIBRINOGEN; HUMANS; MICE; MICE, KNOCKOUT;

MUS;

EID: 60349106776     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.01.045     Document Type: Article

References (25)

1. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
2. Kisker O., Becker C.M., Prox D., et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 61 (2001) 7669-7674
3. Dhanabal M., Ramchandran R., Volk R., et al. Endostatin: yeast production mutants, and antitumor effect in renal cell carcinoma. Cancer Res. 59 (1999) 189-197
4. Eisterer W., Jiang X., Bachelot T., Pawliuk R., Abramovich C., Leboulch P., Hogge D., and Eaves C. Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol. Ther. 5 (2002) 352-359
5. Pawliuk R., Bachelot T., Zurkiya O., Eriksson A., Cao Y., and Leboulch P. Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol. Ther. 5 (2002) 345-351
6. Marshall M. Cancer therapy: setbacks for endostatin. Science 295 (2002) 2198-2199
7. Boehm T., Folkman J., Browder T., and O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404-407
8. Jouanneau E., Alberti L., Nejjari M., Treilleux I., Vilgrain I., Duc A., Combaret V., Favrot M., Leboulch P., and Bachelot T. Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. J. Neurooncol. 51 1 (2001) 11-18
9. Li B., Wu X., Zhou H., Chen Q., and Luo Y. Acid-induced unfolding mechanism of recombinant human endostatin. Biochemistry 43 (2004) 2550-2557
10. Zhou H., Wang W., and Luo Y. Contributions of disulfide bonds in a nested pattern to the structure, stability, and biological functions of endostatin. J. Biol. Chem. 280 (2005) 11303-11312
11. He Y., Zhou H., Tang H., and Luo Y. Deficiency of disulfide bonds facilitating fibrillogenesis of endostatin. J. Biol. Chem. 281 (2006) 1048-1057
12. Doolittle R.F. Fibrinogen and fibrin. Annu. Rev. Biochem. 53 (1984) 195-229
13. Herrick S., Blanc-Brude O., Gray A., and Laurent G. Fibrinogen. Int. J. Biochem. Cell Biol. 31 (1999) 741-746
14. Brown L.F., Asch B., Harvey V.S., Buchinski B., and Dvorak H.F. Fibrinogen influx and accumulation of cross-linked fibrin in mouse carcinomas. Cancer Res. 48 (1988) 1920-1925
15. Palumbo J.S., Potter J.M., Kaplan L.S., Talmage K., Jackson D.G., and Degen J.L. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 62 23 (2002) 6966-6967
16. Ploplis V.A., Wilberding J., McLennan L., Liang Z., Cornelissen I., DeFord M.E., Rosen E.D., and Castellino F.J. A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice. Am. J. Pathol. 157 (2000) 703-708
17. Mosesson M.W., and Umfleet R.A. The cold-insoluble globulin of human plasma. I. Purification, primary structure, and relationship to fibrinogen and other cold-insoluble fraction components. J. Biol. Chem. 245 (1970) 5728-5736
18. Smith R.L., and Griffin S.A. Separation of plasma fibronectin from associated hemagglutinating activity by elution from gelatin-agarose at pH 5.5. Thrombosis Res. 37 (1985) 91-101
19. H. Tang, Y. Fu, Y. Cui, Y. He, X. Zeng, V.A. Ploplis, F.J. Castellino, Y. Luo, Fibrinogen has chaperone-like activity, Biochem. Biophys. Res. Commun. 378 (2009) 662-667.
20. Morbidelli L., Donnini S., Chillemi F., Giachetti A., and Ziche M. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Clin. Cancer Res. 9 (2003) 5358-5369
21. Tjin Tham Sjin R.M., Satchi-Fainaro R., Birsner A.E., Ramanujam V.M., Folkman J., and Javaherian K. A 27-amino acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res. 65 (2005) 3656-3663
22. Margineanu I., and Ghetie V. A selective model of plasma protein catabolism. J. Theor. Biol. 90 (1981) 101-110
23. Suehiro K., Mizuguchi J., Nishiyama K., et al. Fibrinogen binds to integrin alpha(5)beta(1) via the carboxyl-terminal RGD site of the Aalpha-chain. J. Biochem. (Tokyo) 128 (2000) 705-710
24. Pluskota E., and D'Souza S.E. Fibrinogen interactions with ICAM-1 (CD54) regulate endothelial cell survival. Eur. J. Biochem. 267 (2000) 4693-4704
25. Langenbach K.J., and Sottile J. Identification of protein-disulfide isomerase activity in fibronectin. J. Biol. Chem. 274 (1999) 7032-7038